Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
暂无分享,去创建一个
Ming-Hui Chen | Anthony V D'Amico | A. D'Amico | D. Lubeck | P. Carroll | Ming-Hui Chen | J. Moul | Peter R Carroll | Judd W Moul | Leon Sun | Deborah Lubeck | Leon L Sun | Peter R. Carroll | Ming-Hui Chen | Peter R Carroll | Deborah P. Lubeck
[1] Anthony V D'Amico,et al. Predicting prostate-specific antigen recurrence established: now, who will survive? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Oesterling,et al. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. , 1997, The Urologic clinics of North America.
[3] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[4] D. Wood,et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.
[5] P. Carroll,et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. , 1998, The Journal of urology.
[6] Debashis Kushary,et al. Bootstrap Methods and Their Application , 2000, Technometrics.
[7] H M Sandler,et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. , 1997, International journal of radiation oncology, biology, physics.
[8] A. D'Amico,et al. Combined-modality staging for localized adenocarcinoma of the prostate. , 2001, Oncology.
[9] P Flandre,et al. Estimating the proportion of treatment effect explained by a surrogate marker. , 1999, Statistics in Medicine.
[10] J. Bishoff,et al. Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era , 2001 .
[11] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[12] J. Dekernion,et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.
[13] M J Daniels,et al. Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.
[14] D. Gleason,et al. Histologic Grading and Staging of Prostatic Carcinoma , 1981 .
[15] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[16] James D. Cox,et al. Consensus statement: Guidelines for PSA following radiation therapy , 1997 .
[17] R. Dunn,et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. , 2000, International journal of radiation oncology, biology, physics.
[18] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[19] Jeffrey J. Gaynor,et al. On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .
[20] G E Hanks,et al. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Schemper,et al. The relative importance of prognostic factors in studies of survival. , 1991, Statistics in medicine.
[22] A. D'Amico,et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Lubeck,et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.
[24] M. Kattan,et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Bergstralh,et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. , 2001, Mayo Clinic proceedings.
[26] J. Moul. Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.
[27] D. Lubeck,et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. , 2001, The Journal of urology.
[28] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[29] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[30] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[31] A. Renshaw,et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Renshaw,et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[34] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[35] T. Fleming,et al. Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.